YK-012
- Generic Name
- YK-012
Study of YK012 in Primary Membranous Nephropathy
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Excyte Biopharma Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT06982729
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Excyte Biopharma Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT06580301
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Excyte Biopharma Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT06565689
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath